Active Ingredient History
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Meningococcal Vaccines (approved 2015)
Communicable Diseases (Phase 2)
Healthy Volunteers (Phase 3)
HIV (Phase 4)
HIV Infections (Phase 4)
Infant, Premature, Diseases (Phase 4)
Meninges (Phase 3)
Meningitis, Meningococcal (Phase 4)
Meningococcal Infections (Phase 4)
Meningococcal Vaccines (Phase 3)
Neisseria meningitidis (Phase 2)
Respiratory Syncytial Virus Infections (Phase 1)
Risk-Taking (Phase 3)
Splenectomy (Phase 3)
Unsafe Sex (Phase 3)
Vaccination (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue